Objectives: The primary aim of the study was to investigate whether there is a difference in plasma B-type natriuretic peptide (BNP) levels among the left ventricular systolic dysfunction caused by different types of heart disease.
Methods And Results: Plasma BNP was measured in patients with left ventricular systolic dysfunction as a result of mitral valve regurgitation (n=26), hypertension (n=36), coronary heart disease (n=37) and dilated cardiomyopathy (n=32). The left ventricular end-diastolic diameter and ejection fraction were assessed with echocardiography. The valvular heart disease group had more women and was younger (p < 0.05). There was no significant difference in the New York Heart Association functional class, left ventricular end-diastolic diameter and ejection fraction among the four groups (p < 0.05). The average plasma BNP was also similar among the four groups of patients. In each group, a significant correlation between the levels of BNP and the left ventricular end-diastolic diameter or ejection fraction was identified (p < 0.001).
Conclusion: Plasma BNP concentrations during left ventricular systolic dysfunction are associated with left ventricular diameter and function, but they are not determined by the causes of the heart failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2143/AC.60.3.2005008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Feasibility and preliminary efficacy of a physical activity intervention in adults with lymphoma undergoing treatment.
Pilot Feasibility Stud
January 2025
Department of Internal Medicine - Cardiology, Virginia Commonwealth University, West Hospital 8th Floor, North Wing, Richmond, VA, 23298, USA.
Background: To determine the feasibility, acceptability, and preliminary efficacy of a 6-month tailored non-linear progressive physical activity intervention (PAI) for lymphoma patients undergoing chemotherapy.
Methods: Patients newly diagnosed with lymphoma (non-Hodgkin (NHL) or Hodgkin (HL)) were randomized into the PAI or healthy living intervention (HLI) control (2:1). Feasibility was assessed by examining accrual, adherence, and retention rates.
Aortic valve repair with sinus plication for a regurgitant bicuspid aortic valve: a case report.
Gen Thorac Cardiovasc Surg Cases
January 2025
Osaka Metropolitan University Graduate School of Medicine, 1-4-3, Asahimachi, Abeno-Ku, Osaka, 545-8585, Japan.
Background: Repair of the regurgitant bicuspid aortic valve is an attractive alternative to valve replacement. Although good long-term outcomes have been reported, postoperative aortic stenosis remains a major late cause of repair failure in bicuspid aortic valves. Sinus plication is effective for creating a more symmetrical commissural angle, leading to a decrease in the mean transvalvular pressure gradient.
View Article and Find Full Text PDF2-[F]Fluoropropionic Acid PET Imaging of Doxorubicin-Induced Cardiotoxicity.
Mol Imaging Biol
January 2025
Department of Radiology, Weill Cornell Medicine, 413 E 69th Street, Room BB-1604, New York, NY, 10021, USA.
Purpose: Treatment of pediatric cancers with doxorubicin is a common and predictable cause of cardiomyopathy. Early diagnosis of treatment-induced cardiotoxicity and intervention are major determinants for the prevention of advanced disease. The onset of cardiomyopathies is often accompanied by profound changes in lipid metabolism, including an enhanced uptake of short-chain fatty acids (SCFA).
View Article and Find Full Text PDFDoxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.
Cardiovasc Toxicol
January 2025
Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097, Warsaw, Poland.
Doxorubicin (DOX) is an important drug used in the treatment of many malignancies. Unfortunately DOX causes various side effects, with cardiotoxicity being the most characteristic. Risk factors for DOX induced cardiotoxicity (DIC) include cumulative dose of DOX, preexisting cardiovascular diseases, dyslipidemia, diabetes, smoking, along with the use of other cardiotoxic agents.
View Article and Find Full Text PDFShenmai Injection Reduces Cardiomyocyte Apoptosis Induced by Doxorubicin through miR-30a/Bcl-2.
Chin J Integr Med
January 2025
Department of Cardiovascular Medicine, National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Objective: To explore the molecular mechanism of Shenmai Injection (SMI) against doxorubicin (DOX) induced cardiomyocyte apoptosis.
Methods: A total of 40 specific pathogen-free (SPF) male Sprague Dawley (SD) male rats were divided into 5 groups based on the random number table, including the control group, the model group, miR-30a agomir group, SMI low-dose (SMI-L) group, and SMI high-dose (SMI-H) group, with 8 rats in each group. Except for the control group, the rats were injected weekly with DOX (2 mg/kg) in the tail vein for 4 weeks to induce myocardial injury, and were given different regimens of continuous intervention for 2 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!